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We tested whether ouabain, an inhibitor of the 
sodium pump, can lead to chronic hypertension in 
Long-Evans rats using sensitive 24-h measurements 
of blood pressure. After a control week of vehicle 
isotonic saline infusion (14.4 ml/day), ouabain was 
infused intravenously at 30 pg/kg/day in intact 
(2K) and uninephrectomized UK) Long-Evans rats 
for a total of 4 weeks. Although plasma ouabain 
concentration rose to 0.97 f 0.15 nmoYL with 
ouabain infusion, mean arterial pressure did not 
change in either 2K (A = -0.6 f 1.3 mm Hg) or 1K 
(A = -1.2 + 0.7 mm Hg) rats. These data suggest 
that Long-Evans rats are insensitive to the 
hypertensive effects of ouabain. Am J Hypertens 
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A n endogenous ouabain-like inhibitor of the Na+,K+-ATPase pump has been im- plicated in the pathogenesis of many forms of experimental hypertension, espe- 
cially in volume-dependent hypertension,’ through 
the following mechanism. Inhibition of the sodium 
pump raises intracellular calcium concentration in 
vascular smooth muscle cells, via both membrane de- 
polarization and reduction in the Naf/Ca2+ ex- 
change, resulting in vasoconstriction. It has been 
claimed that endogenous ouabain exhibits physiologic 
and biochemical activities indistinguishable from 
plant-derived ouabain.’ Thus, if endogenous ouabain 
plays an important role in blood pressure control, 
administration of exogenous ouabain at a dose that 
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mimics elevated plasma levels found in hypertension 
should raise blood pressure. 
Indeed, several experimental studies have shown 
that exogenous ouabain can increase blood pressure in 
rats.3-6 Other studies, however,, have failed to demon- 
strate a hypertensive effect of ouabain in rats,7-9 
sheep,l’ dogs,l’ and humans.“! The diverging results 
in rats could be linked to differences in the doses and 
duration of ouabain administration in the strains used 
or in the methods used for blood pressure measure- 
ment. In fact, blood pressure is often measured in rats 
in conditions of stress, by tail-cuff techniques, or for 
short recording periods during recovery from surgery 
and anesthesia. The continuous monitoring of arterial 
pressure 24 h a day, a technique that is very sensitive 
to small changes in blood pressure,13 may help to 
resolve this issue. Therefore, tat further test the role of 
an endogenous ouabain-like substance in blood pres- 
sure control, we infused ouabain in Long-Evans rats at 
a dose known to elevate blood pressure in some stud- 
ies3-6 (30 pg/kg/day intravenous [iv] for 28 days) 
while measuring arterial pressure 24 h a day. Further- 
more, we also tested whether reduction in renal mass, 
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a procedure that reduces the kidney’s ability to excrete 
salt and water, can potentiate the pressor effect of 
ouabain. 
MATERIALS AND METHODS 
Animal Preparation Male Long-Evans rats (body 
weight, 350-450 g; 12-24 weeks old) supplied by the 
R. Janvier Center (Le Genest-St-Isle, France) were used 
in this study. All protocols were approved by the State 
Animal Committee. Using sodium pentobarbital anes- 
thesia and aseptic techniques, the rats were instru- 
mented with arterial and venous catheters inserted 
into the left jugular vein and the abdominal aorta (via 
laparotomy), respectively. In some rats, the left kidney 
was removed during the same procedure. The cathe- 
ters were tunneled subcutaneously to the scapular 
region, exteriorized, protected by a flexible coiled steel 
spring, and connected to a double channel swivel 
(Instech Laboratories, Plymouth Meeting, PA). The 
rats were housed in individual metabolic cages, in a 
room maintained at constant temperature (22°C) with 
a 12-h light-dark cycle. The venous line was connected 
to a syringe pump (Kent Scientific, Litchfield, CT). The 
arterial line was flushed daily, filled with heparin 
(1000 USP/mL), and connected to a COBE (Lakewood, 
CO) CDX-III pressure transducer mounted on the cage 
at animal level. Sodium intake was fixed at about 5 
mmol/day using food (25 g rat chow with 0.3% so- 
dium) and isotonic saline intravenous infusion 
(14.4 ml/day). Free access was available to tap water. 
Experimental Protocol After at least 10 days of re- 
covery from surgery followed by a control period of 7 
days of saline vehicle infusion, ouabain (Sigma Chem- 
ical Corp., St. Louis, MO) was started at 30 pg/kg/day 
(10 pL/min) in both intact (2K) and uninephrecto- 
mized (1K) rats for a total of 4 weeks. All solutions 
were prepared aseptically and infused through a Mil- 
lipore filter (0.22 pm, Sterivex-GP, Millipore, Bedford, 
MA). Additional 2K and 1K rats served as time con- 
trols, receiving only the isotonic saline infusion. Daily 
urine samples and biweekly blood samples (0.7 mL) 
were collected for creatinine and electrolyte analysis. 
Continuous Hemodynamic Monitoring The pul- 
satile arterial pressure signal was sent to an 
analog-digital converter (CIO-DASOS, Computer- 
Boards, Mansfield, MA) and analyzed by computer 
using customized software for beat-to-beat analysis.13 
The analog signal was sampled at 500 Hz, for 5-s 
periods every 30 s, for 22 h daily (from 10 AM to 8 AM 
the next day). For each rat, the daily mean arterial 
pressure and heart rate were thus computed as the 
average of 2640 sampling periods, and weekly results 
are reported as the average of 7 consecutive days. 
Analytical Measurements Sodium, potassium, and 
creatinine concentrations of urine and blood samples 
were measured by flame photometry (model IL 943, 
Instrumentation Laboratories, Lexington, MA) and by 
the kinetics of Jaffe (Beckman creatinine analyzer 2, 
Fullerton, CA), respectively. At the end of the exper- 
iments, a 5-mL arterial blood sample was collected in 
EDTA tubes for measurement of plasma ouabain con- 
centration in duplicate by enzyme immunoassay (Du- 
Pont Ouabain EIA kit, DuPont, Boston, MA). 
Statistical Analysis The data were analyzed by anal- 
ysis of variance for repeated measurements and Dun- 
nett’s multiple comparison t test when applicable. Sta- 
tistical significance was taken as P < .05. All data are 
expressed as mean 2 SEM. 
RESULTS 
During the 5 weeks of observation, food and water 
intake, 24-h urinary sodium and potassium excretion, 
plasma sodium and potassium concentration, and glo- 
merular filtration rate remained stable and were un- 
affected by the ouabain infusion. As shown in Figure 
1, mean arterial pressure did not change throughout 
the ouabain infusion. Control values were 98.4 t 1.9 
mm Hg in 2K rats (n = 5) and 99.4 5 1.3 mm Hg in 1K 
rats (n = 5), and values during the fourth week of 
ouabain infusion were 97.9 + 1.8 mm Hg in 2K rats 
and 98.2 t 0.6 mm Hg in 1K rats. Heart rate was also 
unaffected by the ouabain infusion. In 2K rats heart 
rate was 338 ? 14 beats/min during the control week 
and 331 + 9 beats/min during the fourth week of 
ouabain infusion. In 1K rats heart rate was 342 + 24 
beats/min during the control week and 341 ? 12 
beats/min during the fourth week of ouabain infu- 
sion. Plasma ouabain concentrations measured at the 
end of the experiment were 0.02 -+ 0.002 nmol/L in 
time-control rats (2K+lK), 0.93 + 0.17 nmol/L in 2K 
ouabain rats, and 1.02 ? 0.26 nmol/L in 1K ouabain 
rats (or 0.97 5 0.15 nmol/L when 2K and 1K data are 
pooled). 
DISCUSSION 
The major finding of the present study is that exoge- 
nous ouabain infused for 4 weeks, at a dose that raises 
plasma ouabain concentration in the nanomolar range, 
had no effect on systemic blood pressure or heart rate 
in Long-Evans rats, even under conditions of reduced 
renal mass and slightly elevated sodium intake (=5 
mmol/day). Although endogenous ouabain is struc- 
turally indistinguishable from plant-derived ouabain 
by mass spectrometry,2 a possible limitation of our 
study is that endogenous ouabain could be an isomer 
of ouabain and may produce a more profound inhibi- 
tion of vascular smooth muscle sodium pump iso- 
forms. However, in preliminary experiments from our 
laboratory, we have been unable to observe changes in 
blood pressure with a higher infusion rate of ouabain 
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FIGURE 1. Effects of a 4-week infusion of ouabain (ouabain 
group) or isotonic saline vehicle (time-control group) on mean 
arterial pressure in intact 2K rats (A) and in uninepkrectomized 
IK rats (B) following a first week of control saline infision 
(control week). WK, week. Data are expressed as mean ? SEM. 
(150 Kg/kg/day for 28 days) in uninephrectomized 
Long-Evans rats (n = 4). A major strength of our study 
is that arterial pressure was measured 24 h a day in 
conscious undisturbed animals, a method that pro- 
vides highly reproducible values from day to dayI 
and is thus very sensitive to small changes in blood 
pressure. Our data therefore strongly suggest that 
Long-Evans rats are resistant to the hypertensive ef- 
fects of ouabain. 
The role of an endogenous ouabain-like inhibitor of 
the Na+,K+-ATPase pump in blood pressure control 
remains controversial. Several studies have reported 
an increase in blood pressure with ouabain in different 
strains of rats. For example, Manunta et al3 infused 
ouabain at different doses (3, 10, and 30 pg/kg/day 
subcutaneously for 5 weeks by osmotic minipumps) in 
normal Sprague-Dawley rats maintained under a nor- 
mal salt intake and found a dose-dependent increase 
in blood pressure measured once a week using the 
tail-cuff method. Similarly, Kurashina et al6 injected 
ouabain (27.8 pg/kg/day intraperitoneally for 6 
weeks) in Sprague-Dawley rats .with a high salt intake 
and found an elevation of blood pressure measured 
with an indwelling catheter usi.ng anesthesia. An in- 
crease in blood pressure was also found in Wistar rats, 
whether ouabain was injected intraperitoneally4 (27.8 
pg/kg/day for 28 days; BP measured by the tail-cuff 
method), infused5 (10 pg/day), or released from sub- 
cutaneously implanted pellets5 (25-75 pg/day for 2 
weeks; BP measured by indwelling catheter during 
recovery from surgery and anesthesia). 
In contrast, other studies in Sprague-Dawley rats 
have reported no change in blood pressure (measured 
by tail cuff) with ouabain adm:inistration.7-9 Some of 
these studies”’ have been criticized because ouabain 
was administered at higher doses or for too short a 
period. High doses of ouabain can cause cardiotoxicity 
and sensitize arterial baroreceptor,5 and could there- 
fore attenuate the responses to ouabain. Although this 
could explain the negative results of Nirasawa et al9 
(ouabain 1, 5, or 10 mg/kg/day intraperitoneally for 
26 days) and Yasujima et al’ (ouabain 1.2 mg/kg/day 
iv for 6 days), Li et al7 infused ouabain at much lower 
doses (10 to 100 pg/kg/day intraperitoneally by os- 
motic minipumps for 28 days) and were unable to 
detect any change in arterial bl’ood pressure. 
Adding to the controversy is the method of blood 
pressure measurement. All rat studies mentioned here 
report recordings of blood pressure for short periods 
only, often in the conditions of possible stress related 
to tail-cuff measurement, which involves heating and 
restraint, or measurements witih indwelling catheters 
during or shortly after surgery and anesthesia. This 
may lead to increased background noise in blood pres- 
sure measurements and possibly to conflicting results. 
In our study the animals were allowed to recover for 
at least 10 days after surgery, and blood pressure was 
measured 24 h a day in the conscious undisturbed 
animal, a method that should detect very small 
changes in blood pressure.13 
However, because we used a different strain of rats 
(Long-Evans), our study does not exclude the possi- 
bility that an endogenous ouabain-like substance may 
play a role in long-term blood pressure control of 
Wistar or Sprague Dawley rats. Some authors have 
reported that Long-Evans rats are less sensitive to 
certain hypertensive agents, such as chronic cold ex- 
posure14 and sucrose loading.15 However, unine- 
phrectomy increases blood pressure markedly during 
sucrose loading.15 Furthermore, Long-Evans rats do 
not seem to be resistant to mineralocorticoid-induced 
hypertension, as mineralocorticoid administration 
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leads to similar increases in blood pressure in Long- 
Evans rats, compared with Sprague Dawley rats.i6 
Nevertheless, we cannot exclude the possibility that 
Long-Evans rats may have a different distribution of (Y 
isoforms of the sodium pump in comparison to other 
rat species. Long-Evans rats could have a greater pro- 
portion of the CY 1 isoform in their vascular smooth 
muscle, an isoform that is particularly resistant to 
ouabain.i7 Further experiments remain necessary to 
test this possibility. 
In summary, our data suggest that long-term infu- 
sion of ouabain that yields plasma concentrations in 
the nanomolar range is unable to raise arterial pres- 
sure in conscious Long-Evans rats, even under condi- 
tions of reduced renal mass and a slight increase in 
sodium intake. In conclusion, an endogenous ouabain- 
like inhibitor of the Na+,K+-ATPase pump does not 
seem to play an important role in long-term blood 
pressure control in Long-Evans rats. 
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